Dr. Eunyoung Ko

• Specialities: Breast Surgery

Eunyoung Ko, M.D., is Breast Surgery consultant of Oncology Center.

Major areas of interests are Breast cancer, Benign breast disease, and Oncoplastic surgery.

She has overall 19 years of professional experience.

After receiving medical degree from Seoul National University College of Medicine, she had 8 years of residency and fellowship training in the Department of Surgery at Seoul National University Hospital.

Areas of Interest

• Breast cancer
• Benign breast disease
• Oncoplastic surgery

Education

• MD, Seoul National University College of Medicine, Seoul, Korea
• MS, Seoul National University College of Medicine, Seoul, Korea

Specialty Training

Fellowship
Surgery, Seoul National University Hospital, Seoul, Korea

Residency
Surgery, Seoul National University Hospital, Seoul, Korea

Internship
Seoul National University Hospital, Seoul, Korea

Working Experience

• Consultant, Department of Breast Surgery, Sheikh Khalifa Specialty Hospital, RAK, UAE
• Clinical Professor, Department of Surgery, Seoul National University Boramae Hospital, Seoul, Korea
• Chief of Breast Care Center, Seoul National University Boramae Hospital, Seoul, Korea
• Chief of Breast Cancer Center, Dongnam Institute of Radiological & Medical Science, Busan, Korea

Academic Activities

Publication

• Management of benign papilloma without atypia diagnosed at ultrasound-guided core needle biopsy: Scoring system for predicting malignancy. European Journal of Surgical Oncology. Available online 13 November 2017. 10.1016/j.ejso.2017.10.214.
• Early outcome of the Korean Diagnosis-Related Groups payment system for appendectomy. Ann Surg Treat Res. 2015 Mar;88(3):126-32. doi: 10.4174/astr.2015.88.3.126. PubMed PMID: 25741491; PubMed Central PMCID:PMC4347045.
• Preoperative serum tissue polypeptide-specific antigen is a valuable prognostic marker in breast cancer. Int J Cancer. 2013 Feb 15;132(4):875-81. doi: 10.1002/ijc.27727. PubMed PMID: 22815188.
• EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. Mol Cell. 2012 Nov 30;48(4):572-86. doi: 10.1016/j.molcel.2012.09.004. PubMed PMID: 23063525. Co-author
• SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatment. Oncogene. 2013 Mar 21;32(12):1508-17. doi: 10.1038/onc.2012.176. PubMed PMID: 22665050.
• The CD49d+/high subpopulation from isolated human breast sarcoma spheres possesses tumor-initiating ability. Int J Oncol. 2012 Mar;40(3):665-72. doi:10.3892/ijo.2011.1289. PubMed PMID: 22159714.
• 17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy. Exp Ther Med. 2011 Sep;2(5):799-804. PubMed PMID: 22977578; PubMed Central PMCID: PMC3440692.
• Transglutaminase 2 facilitates the distant hematogenous metastasis of breast cancer by modulating interleukin-6 in cancer cells. Breast Cancer Res. 2011 Oct 3;13(5):R96. doi:10.1186/bcr3034. PubMed PMID: 21967801; PubMed Central PMCID: PMC3262209.
• NFIB is a potential target for estrogen receptor-negative breast cancers. Mol Oncol.2011 Dec;5(6):538-44. doi: 10.1016/j.molonc.2011.08.002. PubMed PMID: 21925980.
• Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2011 Feb;126(1):93-9. doi: 10.1007/s10549-010-1315-z. PubMed PMID: 21184268.
• Bcl3-dependent stabilization of CtBP1 is crucial for the inhibition of apoptosis and tumor progression in breast cancer. Biochem Biophys Res Commun. 2010 Sep 24;400(3):396-402. doi: 10.1016/j.bbrc.2010.08.084. PubMed PMID: 20800578.
• The G12 family proteins upregulate matrix metalloproteinase-2 via p53 leading to human breast cell invasion. Breast Cancer Res Treat. 2010 Nov;124(1):49-61. doi: 10.1007/s10549-009-0697-2. PubMed PMID: 20044778.
• The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest. Phytomedicine. 2010 May;17(6):436-40. doi: 10.1016/j.phymed.2009.08.012. PubMed PMID: 19800775.
• Autoantibody to tumor antigen, alpha 2-HS glycoprotein: a novel biomarker of breast cancer screening and diagnosis. Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1357-64. doi: 10.1158/1055-9965.EPI-08-0696. PubMed PMID: 19423516.
• Fibrin glue reduces the duration of lymphatic drainage after lumpectomy and level II or III axillary lymph node dissection for breast cancer: a prospective randomized trial. J Korean Med Sci. 2009 Feb;24(1):92-6. doi:10.3346/jkms.2009.24.1.92. PubMed PMID: 19270819; PubMed Central PMCID: PMC2650992.
• Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol. 2009 May;16(5):1112-21. doi: 10.1245/s10434-009-0334-7. PubMed PMID: 19219507.
• Berberine diminishes the side population and ABCG2 transporter expression in MCF-7 breast cancer cells. Planta Med. 2008 Nov;74(14):1693-700. doi: 10.1055/s-0028-1088313. PubMed PMID: 18951337.
• Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer. Int J Cancer. 2008 Oct 15;123(8):1807-15. doi: 10.1002/ijc.23672. PubMed PMID: 18649361.
• A scoring system to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a comparison with other scoring systems. Ann Surg Oncol. 2008 Aug;15(8):2278-86. doi: 10.1245/s10434-008-9993-z. PubMed PMID: 18528729.
• Sonographic lesion size of ductal carcinoma in situ as a preoperative predictor for the presence of an invasive focus. J Surg Oncol. 2008 Jul 1;98(1):15-20. doi:10.1002/jso.21077. PubMed PMID: 18459155.
• CD24 cross-linking induces apoptosis in, and inhibits migration of, MCF-7 breast cancer cells. BMC Cancer. 2008 Apr 24;8:118. doi: 10.1186/1471-2407-8-118. PubMed PMID: 18433506; PubMed Central PMCID: PMC2386794.
• Berberine inhibits growth of the breast cancer cell lines MCF-7 and MDA-MB-231. Planta Med. 2008 Jan;74(1):39-42. doi: 10.1055/s-2007-993779. PubMed PMID: 18203057.
• Scoring system for predicting malignancy in patients diagnosed with atypical ductal hyperplasia at ultrasound-guided core needle biopsy. Breast Cancer Res Treat. 2008 Nov;112(1):189-95. PubMed PMID: 18060577.
• CD24 expression is positively related with proliferation, adhesion and invasion in MCF-7. Cancer Lett. 2007 Dec 8;258(1):98-108. PubMed PMID: 17950993.